结直肠癌患者血清miR-92a-1表达水平及其诊断意义

毋小玉; 崔发财; 胡敏; 朱亚; 郑培明

doi:10.16766/j.cnki.issn.1674-4152.001968

结直肠癌患者血清miR-92a-1表达水平及其诊断意义

doi: 10.16766/j.cnki.issn.1674-4152.001968

河南省人民医院检验科，河南郑州 450003

基金项目:

国家自然科学基金青年项目 81802094

详细信息

通讯作者:
胡敏，E-mail: yaushz@126.com

中图分类号: R735.3 R735.43
计量
- 文章访问数: 104
- HTML全文浏览量: 62
- PDF下载量: 2
- 被引次数: 0
出版历程
- 收稿日期: 2020-10-11
- 网络出版日期: 2022-02-16

Expression and clinical diagnostic of serum miR-92a-1 in patients with colorectal cancer

Department of Clinical Laboratory, Henan Provincial People's Hospital, Zhengzhou, Henan 450003, China

摘要

摘要: 目的检测结直肠癌患者血清miR-92a-1表达水平并分析其临床意义，探究miR-92a-1单独或联合CEA，CA-199检测对结直肠癌的诊断价值。方法连续收集2018年5月—2019年12月河南省人民医院收治的131例结直肠癌患者、50例结直肠腺瘤患者及50例健康受试者血清，分别采用实时荧光定量PCR(real time quantitative PCR，qRT-PCR)和电化学发光(electrochemiluminescence，ECLIA)法检测并比较3组研究对象血清miR-92a-1、CEA和CA199的表达水平，分析血清miR-92a-1与结直肠癌患者临床病理特征的关系，构建受试者工作特征曲线(receiver operating curves，ROC)，分析miR-92a-1及其联合使用CEA，CA-199检测对结直肠癌的诊断价值。结果血清miR-92a-1、CEA及CA-199在结直肠癌患者中的表达水平显著高于结直肠腺瘤患者和健康对照者，差异有统计学意义(均P < 0.05)；结直肠癌患者血清miR-92a-1表达水平与肿瘤分化程度、TNM分期、淋巴结转移和远处转移有关(均P < 0.05)，而与性别、年龄、肿瘤直径、发病部位无关(均P>0.05)；miR-92a-1诊断结直肠癌的曲线下面积(area under ROC curve，AUC)为0.875(95% CI：0.833~0.918)，诊断敏感性为72.5%，特异性为86%，miR-92a-1联合CEA、CA-199检测诊断结直肠癌的AUC为0.904(95% CI：0.865~0.943)，诊断敏感性为80.2%，特异性为91%。结论 miR-92a-1在结直肠癌中高表达并与肿瘤分化程度、TNM分期、淋巴结转移和远处转移相关，miR-92a-1联合常规肿瘤标志物检测对结直肠癌有较高的诊断价值。
- 结直肠癌 /
- miR-92a-1 /
- 癌胚抗原 /
- 糖类抗原199 /
- 诊断价值
Abstract: Objective This study aimed to investigate the expression of serum miR-92a-1 and its clinical diagnostic value in patients with colorectal cancer (CRC). Methods The serum samples of 131 patients with CRC and 50 patients with colorectal adenomas (CRA), who were hospitalised from May 2018 to December 2019 at the Henan Provincial People's Hospital, were collected, and 50 healthy controls were selected. The expression of serum miR-92a-1, carcinoma embryonic antigen (CEA) and carbohydrate antigen 199 (CA199) were detected by real-time quantitative PCR and electrochemiluminescence (ECLIA) and compared amongst the three groups. The relationship between serum miR-92a-1 and the clinicopathological characteristics of CRC patients was further analysed, and the receiver operating curves (ROC) were constructed to assess the diagnostic value of miR-92a-1 or combination of CEA and CA199 in CRC. Results The expression level of serum miR-92a-1, CEA and CA-199 in CRC patients was significantly higher than those in CRA patients or healthy controls, with statistically significant differences (all P < 0.05). The expression of serum miR-92a-1 in CRC patients was correlated with the degree of differentiation, TNM stage, lymph node metastasis and distant metastasis (all P < 0.05) but not with gender, age, tumour diameter and high risk (all P>0.05). The area under ROC curve (AUC) of miR-92a-1 in the diagnosis of CRC was 0.875 (95% CI: 0.833-0.918), and the sensitivity and specificity were 72.5% and 86%, respectively. The AUC of miR-92a-1 combined with CEA and CA-199 in the diagnosis of CRC was 0.904 (95% CI: 0.865-0.943), and sensitivity and specificity were increased to 80.2% and 91%, respectively. Conclusion The high expression of miR-92a-1 in CRC is related to the degree of differentiation, TNM stage, lymph node metastasis and distant metastasis. miR-92a-1 combined with conventional tumour marker detection has a high diagnostic value for CRC.
- Colorectal cancer /
- MiR-92a-1 /
- Carcinoembryonic antigen /
- CA199 /
- Diagnostic value

HTML全文

图 1 血清miR-92a-1、CEA、CA199单独或联合检测诊断CRC的ROC曲线图

下载: 全尺寸图片幻灯片

表 1 血清miR-92a-1相对表达量与结直肠癌临床病理参数的关系(x ±s)

临床病理参数		例数	miR-92a-1	t值	P值
性别	男	76	1.65±0.62	0.548	0.585
	女	55	1.71±0.61
年龄(岁)	≤60	66	1.73±0.66	1.104	0.272
	>60	65	1.61±0.56
肿瘤直径(cm)	≤4	61	1.65±0.57	0.445	0.657
	>4	70	1.70±0.65
肿瘤发病部位	结肠	49	1.81±0.68	1.967	0.051
	直肠	82	1.59±0.56
TNM分期	Ⅰ~Ⅱ期	23	1.43±0.44	2.130	0.035
	Ⅲ~Ⅳ期	108	1.72±0.63
分化程度	高/中分化	85	1.50±0.54	4.711	< 0.001
	低分化	46	1.99±0.62
淋巴结转移	无	64	1.50±0.52	3.241	0.002
	有	67	1.84±0.66
远处转移	无	103	1.53±0.50	5.951	< 0.001
	有	28	2.22±0.70

下载: 导出CSV

参考文献(20)

[1]	FERLAY J, COLOMBET M, SOERJOMATARAM I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods[J]. Int J Cancer, 2019, 144(8): 1941-1953. doi: 10.1002/ijc.31937
[2]	PAN Q Z, ZHAO J J, YANG C P, et al. Efficacy of adjuvant cytokine-induced killer cell immunotherapy in patients with colorectal cancer after radical resection[J]. Oncoimmunology, 2020, 9(1): 1752563. doi: 10.1080/2162402X.2020.1752563
[3]	HAMERS P A H, ELFERINK M A G, STELLATO R K, et al. Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on real-life data[J]. Int J Cancer, 2021, 148(2): 296-306. doi: 10.1002/ijc.33200
[4]	NOZAWA H, TAKIYAMA H, HASEGAWA K, et al. Adjuvant chemotherapy improves prognosis of resectable stage IV colorectal cancer: a comparative study using inverse probability of treatment weighting[J]. Ther Adv Med Oncol, 2019, 11: 1758835919838960. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM6238190
[5]	LI X, CHEN R, LI Z, et al. Diagnostic value of combining miRNAs, CEA measurement and the FOBT in colorectal cancer screening[J]. Cancer Manag Res, 2020, 12: 2549-2557. doi: 10.2147/CMAR.S238492
[6]	马瀚博, 李怀芳. MicroRNA在卵巢癌早期诊断及预后中应用的研究进展[J]. 中华全科医学, 2018, 16(5): 826-829. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY201805043.htm
[7]	KHAN S, AYUB H, KHAN T, et al. MicroRNA biogenesis, gene silencing mechanisms and role in breast, ovarian and prostate cancer[J]. Biochimie, 2019, 167: 12-24. doi: 10.1016/j.biochi.2019.09.001
[8]	DANESE E, MONTAGNANA M, LIPPI G, et al. Circulating molecular biomarkers for screening or early diagnosis of colorectal cancer: which is ready for prime time?[J]. Ann Transl Med, 2019, 7(21): 610. doi: 10.21037/atm.2019.08.97
[9]	ZHANG M, JIANG X, JIANG S, et al. LncRNA FOXD2-AS1 regulates miR-25-3p/Sema4c axis to promote the invasion and migration of colorectal cancer cells[J]. Cancer Manag Res, 2019, 11: 10633-10639. doi: 10.2147/CMAR.S228628
[10]	ZENG Z, LI Y, PAN Y, et al. Cancer-derived exosomal miR-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis[J]. Nat Commun, 2018, 9(1): 5395. doi: 10.1038/s41467-018-07810-w
[11]	DONG J, GENG J, TAN W. MiR-363-3p suppresses tumor growth and metastasis of colorectal cancer via targeting SphK2[J]. Biomed Pharmacother, 2018, 105: 922-931. doi: 10.1016/j.biopha.2018.06.052
[12]	PILONIS N D, BUGAJSKI M, WIESZCZY P, et al. Long-term colorectal cancer incidence and mortality after a single negative screening colonoscopy[J]. Ann Intern Med, 2020, 173(2): 81-91. doi: 10.7326/M19-2477
[13]	CARR P R, WEIGL K, EDELMANN D, et al. Estimation of absolute risk of colorectal cancer based on healthy lifestyle, genetic risk, and colonoscopy status in a population-based study[J]. Gastroenterology, 2020, 159(1): 129-138.e9. doi: 10.1053/j.gastro.2020.03.016
[14]	KEMPER M, HENTSCHEL W, KONCZALLA L, et al. Serum Midkine is a clinical significant biomarker for colorectal cancer and associated with poor survival[J]. Cancer Med, 2020, 9(6): 2010-2018. doi: 10.1002/cam4.2884
[15]	陈雪姣, 杨继元. 长链非编码RNA在结直肠癌中的研究进展[J]. 癌症进展, 2020, 18(1): 18-21, 91. https://www.cnki.com.cn/Article/CJFDTOTAL-AZJZ202001006.htm
[16]	BACH D H, HONG J Y, PARK H J, et al. The role of exosomes and miRNAs in drug-resistance of cancer cells[J]. Int J Cancer, 2017, 141(2): 220-230. doi: 10.1002/ijc.30669
[17]	WANG H, PENG R, WANG J, et al. Circulating microRNAs as potential cancer biomarkers: the advantage and disadvantage[J]. Clin Epigenetics, 2018, 10: 59. doi: 10.1186/s13148-018-0492-1
[18]	GHAREIB A F, MOHAMED R H, SAADAWY S F, et al. Assessment of serum microRNA-21 gene expression for diagnosis and prognosis of colorectal cancer[J]. J Gastrointest Cancer, 2020, 51(3): 818-823. doi: 10.1007/s12029-019-00306-w
[19]	BILEGSAIKHAN E, LIU H N, SHEN X Z, et al. Circulating miR-338-5p is a potential diagnostic biomarker in colorectal cancer[J]. J Dig Dis, 2018, 19(7): 404-410. doi: 10.1111/1751-2980.12643
[20]	CHEN E, LI Q, WANG H, et al. MiR-92a promotes tumorigenesis of colorectal cancer, a transcriptomic and functional based study[J]. Biomed Pharmacother, 2018, 106: 1370-1377. doi: 10.1016/j.biopha.2018.07.098